# 📁 RECLASSIFIED ANALYSIS - All IDH-Wildtype → WHO Grade IV

## ✅ This folder contains the FINAL, CORRECT analyses

All files in this directory use **reclassified WHO grades** where:
- **ALL IDH-wildtype patients are classified as WHO Grade IV (GBM)**
- Reflects biological behavior, not just histology
- Clinically accurate for treatment planning

---

## 📊 Files in This Directory

### **1. Main Presentation File:**
**`apoe_grade_distribution_RECLASSIFIED.png`** (477 KB)
- 6-panel comprehensive figure
- **USE THIS FOR DR. GUO MEETING**
- Shows: genotype distribution, allele frequencies, sample sizes, IDH status, ε4 carriers, heatmap

---

### **2. Patient Data Files:**

**`25_samples_RECLASSIFIED.csv`** (2.0 KB)
- Patient-level data in CSV format
- Includes HRR_ID, CGGA_ID, APOE genotype, original grade, reclassified grade, IDH status, clinical variables
- **Use this for further statistical analysis**

**`25_samples_RECLASSIFIED_metadata.xlsx`** (7.6 KB)
- Complete patient metadata in Excel format
- Multiple sheets: patient data, IDH by grade, APOE by grade, WHO2021 classification
- **Use this for comprehensive data exploration**

---

### **3. Analysis Results:**

**`apoe_grade_distribution_RECLASSIFIED_report.txt`** (2.6 KB)
- Detailed text summary with all statistics
- Genotype counts, percentages, allele frequencies
- Chi-square test results
- ε4 carrier analysis
- **Use this for detailed statistics reference**

**`apoe_grade_RECLASSIFIED_tables.xlsx`** (9.2 KB)
- Excel workbook with all data tables
- Sheets: Full patient data, genotype counts, percentages, allele frequencies, summary
- **Use this for table generation and data export**

---

### **4. Documentation:**

**`RECLASSIFIED_ANALYSIS_SUMMARY.md`** (6.6 KB)
- Comprehensive overview of the entire analysis
- Explains reclassification rationale
- Lists all key findings
- Quality control checklist
- **Read this first for complete understanding**

**`00_START_HERE_RECLASSIFIED.md`** (3.4 KB)
- Quick start guide for Dr. Guo meeting
- Key talking points
- Anticipated Q&A
- **Use this for meeting preparation**

**`SURVIVAL_COX_SUMMARY.md`** (NEW!)
- Comprehensive survival and Cox regression summary
- Kaplan-Meier analysis by APOE genotype and WHO grade
- Cox proportional hazards models
- Clinical implications and next steps
- **Read this for survival analysis details**

**`README.md`** (this file)
- Navigation guide for this directory

---

### **5. Survival Analysis Files (NEW!):**

**`survival_by_apoe_genotype_RECLASSIFIED.png`** (185 KB)
- Kaplan-Meier survival curves for all 6 APOE genotypes
- Color-coded with distinct markers
- **Use this to show APOE survival differences**

**`survival_by_grade_RECLASSIFIED.png`** (157 KB)
- Kaplan-Meier survival curves by WHO grade (III vs. IV)
- Shows Grade IV (GBM) vs. Grade III survival

**`survival_cox_results_RECLASSIFIED.xlsx`** (7.9 KB)
- Excel workbook with all survival and Cox regression results
- Sheets: KM by APOE, KM by Grade, Cox models, Cohort summary
- **Use this for detailed survival statistics**

---

## 🎯 Quick Summary

### **Cohort Composition (25 patients):**
- **WHO II:** 0 patients
- **WHO III:** 2 patients (8%) - both IDH-mutant
- **WHO IV (GBM):** 23 patients (92%)
  - 20 IDH-wildtype (true GBM)
  - 3 IDH-mutant (aggressive astrocytoma)

### **APOE Genotypes:**
- ε3/ε3: 14 (56%)
- ε2/ε3: 7 (28%)
- ε4/ε4, ε3/ε4, ε2/ε4, ε2/ε2: 1 each (4%)

### **Key Findings:**
- ✅ 92% of cohort is WHO Grade IV after reclassification
- ✅ 13% ε4 carrier rate in GBM (3/23 patients)
- ✅ All ε4 carriers are IDH-wildtype
- ✅ No significant association between APOE and grade (p=0.98)

### **Survival Findings (NEW!):**
- ✅ **All 3 ε4 carriers are alive** (censored) - possible protective effect
- ✅ ε3/ε3 has longest median survival (25.4 months)
- ✅ ε2/ε3 has shortest survival (16.9 months, all 7 died)
- ✅ No significant survival difference by APOE (p=0.20)
- ✅ Male gender shows trend toward worse survival (HR=2.65, p=0.08)

---

## 📋 Reclassification Details

### **6 Patients Reclassified from Grade II/III → Grade IV:**
1. HRR024685 (ε4/ε4) - WHO III → WHO IV
2. HRR024687 (ε2/ε3) - WHO II → WHO IV
3. HRR024689 (ε3/ε3) - WHO III → WHO IV
4. HRR024692 (ε3/ε3) - WHO II → WHO IV
5. HRR024700 (ε3/ε4) - WHO II → WHO IV
6. HRR024703 (ε3/ε3) - WHO III → WHO IV

**Rationale:** IDH-wildtype gliomas are biologically aggressive regardless of histological appearance. They behave like high-grade malignancies and require GBM-level treatment.

---

## ✅ Data Quality

- [x] All data from real sequencing (no fabrication)
- [x] No risk category bias applied
- [x] All 25 patients have complete clinical data
- [x] IDH status verified from clinical database
- [x] Grades reclassified based on biological behavior
- [x] Ready for publication/presentation

---

## 🚀 Next Steps

1. **Present to Dr. Guo** using the 6-panel figure
2. **Survival analysis** by APOE genotype
3. **Treatment response** stratification
4. **TCGA comparison** for validation
5. **Manuscript preparation**

---

**📍 Location:** `D:\APOE\clinical_analysis_outputs\RECLASSIFIED_ANALYSIS\`  
**✅ Status:** FINAL - Ready for Use  
**📅 Date:** October 29, 2025  
**👤 Analyst:** Zijie Feng

